...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Human reproduction update >Placental protein 13 (PP13): A new biological target shifting individualized risk assessment to personalized drug design combating pre-eclampsia
【24h】

Placental protein 13 (PP13): A new biological target shifting individualized risk assessment to personalized drug design combating pre-eclampsia

机译：胎盘蛋白13（PP13）：一种新的生物学目标，将个体化的风险评估转变为对抗先兆子痫的个性化药物设计

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Pre-eclampsia affects 2-7% of all pregnant women and is a major cause of maternal and fetal morbidity and mortality. The etiology of pre-eclampsia is still unknown but it is well documented that impaired placentation is a major contributor to its development. One of the placenta-specific proteins is placental protein 13 (PP13). Lower first trimester levels of maternal serum PP13 and its encoding placental mRNA are associated with the development of both early and late-onset severe pre-eclampsia. In cases where this protein is mutated, the frequency of pre-eclampsia is higher.methods: 19 out of 68 studies on PP13, published between January 2006 and September 2012, were used to evaluate the value of maternal blood PP13 as a marker of pre-eclampsia. results: A meta-analysis presented in this review shows that low serum levels of PP13 in the first trimester of pregnancy can predict the development of pre-eclampsia later in pregnancy. Although some functions of this protein have been assessed in in vitro experiments, the in vivo functions of PP13 are still unknown, especially when circulating in the maternal bloodstream. A recent pilot study has shown that in gravid rats PP13 causes significant vasodilatation, reduced blood pressure and increased maternal uterine artery remodeling. conclusion: Reviewing these effects of PP13, the authors propose the use of PP13 as a new drug candidate. Replenishing PP13 in those women with low serum levels early in pregnancy may help prepare their vasculature for pregnancy. This novel pharmacological approach to combat pre-eclampsia is presented as a new direction to transfer from individualized risk to personalized prevention.
机译：子痫前期影响所有孕妇的2-7％，并且是母婴发病率和死亡率的主要原因。先兆子痫的病因仍未知，但是有充分的文献证明胎盘受损是其发展的主要因素。胎盘特异性蛋白之一是胎盘蛋白13（PP13）。孕妇血清PP13及其编码的胎盘mRNA的孕早期较低水平与早发和晚发的严重先兆子痫的发展有关。方法：2006年1月至2012年9月发表的68项关于PP13的研究中有19项被用来评估母体血液中PP13的价值，作为先兆子痫的标志物。 -子痫。结果：本评价的荟萃分析显示，妊娠早期三个月的血清低水平的PP13可以预测妊娠晚期子痫的发展。尽管已经在体外实验中评估了该蛋白的某些功能，但PP13的体内功能仍是未知的，尤其是在母体血液中循环时。最近的一项先导研究表明，在妊娠大鼠中，PP13引起明显的血管扩张，血压降低和母体子宫动脉重塑增加。结论：回顾PP13的这些作用，作者建议使用PP13作为新药候选物。那些在怀孕初期血清水平低的女性中补充PP13可能有助于为妊娠准备血管。提出了这种抗先兆子痫的新药理方法，将其从个体风险转移到个性化预防的新方向。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号